摘要
①目的 探讨 p5 3、c erbB 2、CD4 4v6与雌激素受体 (ER)和孕激素受体 (PR)联合检测对子宫内膜样腺癌预后判断的意义。②方法 应用免疫组化方法 ,检测 88例子宫内膜腺癌标本p5 3、c erbB 2、CD4 4v6、ER和PR的表达情况 ,分析其与组织学分级、临床分期之间的关系。③结果 子宫内膜样腺癌 p5 3、c erbB 2与CD4 4v6的阳性表达率分别为 6 4 .8%、6 2 .5 %和 5 6 .8% ,并且随临床分期和恶性程度增高 ,阳性表达率亦增高 ,差异有显著性(χ2 =4 .1 9～ 1 3.4 5 ,P <0 .0 5、0 .0 1 )。ER和PR在子宫内膜样腺癌中的表达率分别为 76 .1 %和 73.3% ,其表达率随分化程度的降低而降低 (χ2 =2 2 .83、1 6 .5 7,P <0 .0 1 ) ,且分期越晚 ,表达率越低 (χ2 =1 9.2 7、1 0 .1 4 ,P <0 .0 1 )。④结论 子宫内膜样腺癌组织中 p5 3、c erbB 2、CD4 4v6阳性表达及ER和PR阴性的病人预后差。
Objective To study the correlation between the expression of p53, c-erbB-2, CD44v6, estrogen receptors(EP), and progesterone receptors(PR) and grade of malignancy and clinical stages of endometrioid adenocarcinoma(EA). Me- thods 88 patients with EA were examined with immunohistochemical technique S-P method. Results The positive rate of p53, c-erbB-2, and CD44v6, were 64.8%, 62.5%, and 56.8% respectively. Their expression levels were strongly associated with the clinical stages and the grade of malignancy (χ 2=4.19-13.45,P<0.01,0.05). The expression of ER and PR were associated with the grade of malignancy (χ 2=22.83,16.57,Ρ<0.01) and the period of clinical stages (χ 2= 19.27 ,10.14,P<0.01). Conclusion The patients with positive p53, c-erbB-2, and CD44v6 and negative ER and PR had poor prognosis.
出处
《青岛大学医学院学报》
CAS
2004年第1期42-43,共2页
Acta Academiae Medicinae Qingdao Universitatis
关键词
子宫内膜样腺癌
P53
c—erbB-2
CD44V6
雌孕激素受体
联合检测
endometrial neoplasmas
immunohistochemistry
gene, p53
gene, c-erbB-2
protein,CD44v6
receptors, estrogen
receptors, progesterone
